Aptuit & Alios BioPharma to Collaborate
Â
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, recently announced that Aptuit and Alios BioPharma, South San Francisco, California, are collaborating in lead optimization projects for two of Alios’ anti-viral targets.
Mr. Needleman stated that Aptuit has put in place a multidisciplinary, cross-functional team of scientific professionals representing computational chemistry, medicinal chemistry, analytical chemistry, and Drug Metabolism and Pharmacokinetics (DMPK) capabilities. He said, “Under the leadership of Aptuit scientists, the team is working with Alios scientists in an environment of openness and honest communications as we advance the discovery process of their novel chemical series.”
Although the terms of the agreement were not disclosed, Mr. Needleman explained, “We appreciate the confidence and trust that Alios has placed in our experienced hands. The collaboration represents another good example of how Aptuit’s drug discovery capabilities can be applied to all therapeutic areas, including anti-viral, central nervous system, oncology, antibacterial, respiratory, and more.”
Leonid Beigelman, Chief Scientific Officer at Alios, added, “We are very pleased to be working with Aptuit’s multidisciplinary drug discovery team. They have an exceptional track record of success in delivering IND candidates with highly druglike properties optimized for favorable pharmacokinetic properties in humans.”
Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting, and Aptuit INDiGO (a program that accelerates drug development) are offered as stand alone or integrated services. For more information, visit www.aptuit.com.
Total Page Views: 1250
